Illumina selloff a buying opportunity, says Piper Jaffray
Piper Jaffray analyst William Quirk recommends using today's selloff in shares of Illumina as a buying opportunity. The stock traded down 24% last night after the company reported preliminary Q3 revenue of $607M, below the Street's $628.3M estimate. A lower number of HiSeq 2500/4000 installs as well as a HiSeq X Ten placement slip drove the revenue miss, Quirk tells investors in a research note. He notes, however, that his HiSeq X checks found the pipeline remains "very strong" at 95 systems, with a majority driven by the Chinese precision medicine program. He views $130 as a "technical floor" for the shares and dropped his price target for Illumina to $150 from $163. Quirk keeps an Overweight rating on the name.